HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Master Thesis

Faisabilité, tolérance et efficacité du Taxotère-Cisplatine-5FU (TPF) dans la stratégie de prise en charge des carcinomes épidermoïdes de la tête et du cou, en Bretagne et Pays de Loire

Abstract : BACKGROUND – In locally advanced squamous-cells head and neck carcinoma (HNSCC), chemotherapy improves outcomes both with concomitant radiotherapy or for laryngeal preservation (LP). While combination of Cisplatin, Docetaxel and 5FU (TPF) is the best treatment in induction chemotherapy, all indications are not currently approved, except for laryngeal preservation. METHODS – Data are reported from a multi-center cohort of 129 patients who received TPF between 2012 and 2016 in frontline of a locally advanced HNSCC, considered to be unresectable or were candidates for organ preservation. Primary endpoint is feasibility of the treatment. Secondary endpoints are tolerance and efficacy. The analysis was conducted in overall population and in a LP subgroup. RESULTS – 96 patients (74.4%) received at least 3 cycles of TPF, of whom 66 (51.1%) without dose reduction. Grade 3 to 5 adverse events occurred in 49 patients (38%), febrile neutropenia and severe infection in 26 (20%). Overall response rate (ORR) after TPF chemotherapy was 61.2%, median overall survival (OS) 43.2 months (95% confidence interval [CI], 26.4 to 59.9), median progression-free survival (PFS) 14.5 months (95% CI, 7.8 to 21.3). For the 37 patients in LP subgroup, 13 (35%) patients were alive with a functional larynx after 3 years. CONCLUSION - TPF induction chemotherapy, performed out of therapeutic trials, remains effective despite its poor feasibility. Heavy toxicity is to be considered, as this treatment has not been proven to be effective besides laryngeal preservation.
Document type :
Master Thesis
Complete list of metadata

https://dumas.ccsd.cnrs.fr/dumas-03543946
Contributor : Santé Rennes 1 Connect in order to contact the contributor
Submitted on : Wednesday, January 26, 2022 - 12:32:26 PM
Last modification on : Wednesday, March 16, 2022 - 3:37:28 AM
Long-term archiving on: : Wednesday, April 27, 2022 - 6:48:20 PM

File

GOISLARD DE MONSABERT_Camille....
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-03543946, version 1

Collections

Citation

Camille Goislard de Montsabert-Connen. Faisabilité, tolérance et efficacité du Taxotère-Cisplatine-5FU (TPF) dans la stratégie de prise en charge des carcinomes épidermoïdes de la tête et du cou, en Bretagne et Pays de Loire. Sciences du Vivant [q-bio]. 2021. ⟨dumas-03543946⟩

Share

Metrics

Record views

3

Files downloads

0